← Back to patent-cliff list
Ensartinib Hydrochloride
Tier C — Watch / tradeEnsartinib Hydrochloride
Xcovery
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ALK, c-Met, ROS
Brand：ENSACOVE
Indications (approved)：Non-small cell lung cancer
Regional status
US
Approved
2024-12-18
EU
Phase III
2016-06-01
China
Approved
2020-11-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ensartinib Hydrochloride?
Approved indications include: Non-small cell lung cancer.
When does the Ensartinib Hydrochloride patent expire?
No public expiry year is available for Ensartinib Hydrochloride yet; this page updates once verified.
How do I get a quote for Ensartinib Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27